143 results on '"Sands, Bruce E"'
Search Results
2. Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease
3. Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn’s Disease Activity
4. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
5. Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions
6. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
7. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod
8. IBD Matchmaking - Rational Combination Therapy
9. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
10. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease
11. Acute severe ulcerative colitis trials: the past, the present and the future
12. Qualitative and Psychometric Evaluation of PROMIS®-29 to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease
13. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure
14. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 G 3 PHASE 3 STUDIES
15. Phase 2 Trial of Anti-TLlA Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
16. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
17. Remote Short Sessions of Heart Rate Variability Biofeedback Monitored With Wearable Technology: Open-Label Prospective Feasibility Study
18. Basket, Umbrella, and Platform Trials: The Potential for Master Protocol -Based Trials in Inflammatory Bowel Disease
19. Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
20. The value of engagement in digital health technology research: Evidence across six unique studies (Preprint)
21. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
22. Longitudinal assessment of sweat-based TNF-alpha in inflammatory bowel disease using a wearable device
23. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
24. Positioning Sphingosine-1 Phosphate Receptor Modulators in Inflammatory Bowel Disease.
25. Impact of Biologics and Small-Molecule Agents on Postoperative Complications in IBD: A Systematic Review.
26. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
27. Differences Between the 2016 and 2022 Food and Drug Administration Guidance—Implications for Design and Interpretation of Clinical Trials in Ulcerative Colitis.
28. Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1.
29. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.
30. Baseline Clinical Factors Are Associated With Risk of Complications in Crohn's Disease: Appraisal of the American Gastroenterological Association Clinical Care Pathway.
31. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
32. Tu1889 REAL-WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD IN ULCERATIVE COLITIS: A MULTICENTER STUDY
33. Mo1736 DIETARY INTERVENTIONS AND SUPPLEMENTATION IN PATIENTS WITH AN ILEAL POUCH-ANAL ANASTOMOSIS; A SYSTEMATIC REVIEW
34. Su1767 SUPER-RESPONDERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE TREATED WITH SUBCUTANEOUS INFLIXIMAB MAINTENANCE THERAPY: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY
35. Su1728 GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY
36. Sa1789 COMPARATIVE RESPONSIVENESS OF DISEASE ACTIVITY INDICES IN MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF THE UNIFI TRIAL
37. 989 EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEEKS 48 AND 96 OF AN OPEN-LABEL MAINTENANCE STUDY AMONG CLINICAL RESPONDERS AT WEEK 8 OF THE PHASE 2B INDUCTION TRIAL
38. Tu1752 MILD CROHN'S DISEASE IS CHARACTERIZED BY A UNIQUE SERUM METABOLOMIC SIGNATURE
39. Mo1757 CLINICAL AND BIOMARKER PREDICTORS OF MILD CROHN'S DISEASE: A COMMUNITY-BASED INCEPTION COHORT STUDY
40. Su1801 PRIMARY EFFICACY AND SAFETY OF MIRIKIZUMAB IN MODERATE TO SEVERE CROHN'S DISEASE: RESULTS OF THE TREAT-THROUGH VIVID 1 STUDY
41. Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY
42. Su1780 EFFICACY OF ONCE-DAILY, ORALLY ADMINISTERED OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE UC AT WEEKS 8, 48, AND 96 BROKEN DOWN BY INDUCTION TREATMENT DOSE
43. Su1758 PLACEBO RATES IN CROHN'S DISEASE: AN INDIVIDUAL PATIENT DATA META-ANALYSIS FROM MULTIPLE RANDOMIZED CONTROLLED TRIALS
44. Su1732 GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
45. 987 EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
46. Tu1996 USE OF AN AUTOMATED, DEEP LEARNING SOFTWARE TO EVALUATE BODY COMPOSITION INCLUDING SKELETAL MUSCLE MASS AND VISCERAL ADIPOSITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
47. Tu1770 DISEASE DURATION IMPACTS INTESTINAL GENE EXPRESSION PROFILES IN CROHN'S DISEASE BUT NOT IN ULCERATIVE COLITIS
48. Tu1751 DISTINCT PERTURBANCES IN METABOLIC PATHWAYS ASSOCIATE WITH DISEASE PROGRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
49. 491 LONGITUDINAL PHYSIOLOGICAL DATA FROM WEARABLE DEVICES IDENTIFY AND DIFFERENTIATE INFLAMMATORY AND SYMPTOMATIC INFLAMMATORY BOWEL DISEASE FLARES
50. 490 LONGITUDINAL ASSESSMENT OF SWEAT-BASED TNF-ALPHA IN INFLAMMATORY BOWEL DISEASE USING A WEARABLE DEVICE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.